The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
about
Structure prediction and validation of the ERK8 kinase domainEmerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancerModulation of host cell signaling pathways as a therapeutic approach in periodontal diseaseRole of P38 MAPK on MMP Activity in Photothrombotic Stroke Mice as Measured using an Ultrafast MMP Activatable Probe.A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition dataIntegrative modelling of the influence of MAPK network on cancer cell fate decisionRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice.Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors.SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade.Using the one-lung method to link p38 to pro-inflammatory gene expression during overventilation in C57BL/6 and BALB/c miceAzastilbenes: a cut-off to p38 MAPK inhibitors.A p38MAPK/MK2 signaling pathway leading to redox stress, cell death and ischemia/reperfusion injury.Preparation of naringenin/ β-cyclodextrin complex and its more potent alleviative effect on choroidal neovascularization in rats.Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling.Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling.sb203580 preconditioning recharges matrix-expanded human adult stem cells for chondrogenesis in an inflammatory environment - A feasible approach for autologous stem cell based osteoarthritic cartilage repair.p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaHeterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer.Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model.In vitro effects of SB202190 on Echinococcus granulosus.An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation.Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation.The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in miceDevelopment of small-molecule therapies for autoimmune diseases.Critical review of p38 MAP kinase inhibitors: a bioanalytical perspective.Childhood nephrotic syndrome--current and future therapies.Research progress of ursolic acid's anti-tumor actions.Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease.Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.Particulate Matter Facilitates C6 Glioma Cells Activation and the Release of Inflammatory Factors Through MAPK and JAK2/STAT3 Pathways.Changes in the free-energy landscape of p38α MAP kinase through its canonical activation and binding events as studied by enhanced molecular dynamics simulationsTranscriptional and posttranscriptional regulation of CXCL8/IL-8 gene expression induced by connective tissue growth factor.
P2860
Q21090822-11B3F701-33F9-44FF-B9AF-88BDB2DBC09BQ26778509-AC60CAD1-537D-4035-B76E-8C7CE93A2EFFQ26852727-543B4BB9-6FB8-4478-9583-BE004376DC9EQ27305326-D73FB1A2-E5A6-4B9A-92E2-158866114951Q27335745-590766CB-C0CD-463C-B7E1-BF079C3FFB08Q28534949-0A563229-FE69-4606-BE67-64A2AB55A5A2Q30593460-033EC7C0-7C17-4F93-AED3-33D5C472ECF8Q33624820-48F1CF1D-EE31-4183-B1C6-7AB295BCC226Q33953835-1BE61902-EF39-4BBB-8FA2-FD55E4A63949Q33996875-9CCE726A-C680-40AA-B41E-D028A6A0445BQ34243088-47FDD490-6472-4590-AE61-75AF7683941CQ34281252-5F3CD889-8FF6-433B-8899-B6321E27E6B1Q34358492-C794EB44-F12F-41ED-B4A2-5562EFA63E21Q34747180-179F8EDD-F124-49B4-839C-EE25A0D88406Q35085128-B053C7F8-44D9-4A1E-B7CE-FA801F2C0A25Q35162838-FE851D21-4C66-424A-B09F-471F1CB2D529Q35236755-0878136E-2D5A-4104-9E18-99968927024EQ35598838-9B01F591-9B63-4BB4-A683-F8EC98041AA3Q35653271-62FE9CC4-7D53-4C8C-A682-B39B8AD8724CQ35776528-6684A621-428F-4689-9877-7E9E32B8726FQ35854886-27D4C9D6-DD12-4555-B6CF-1B8F9635CCBDQ36005424-81AD30FF-1B43-4A03-9C34-2191DB0BFBECQ36194829-28CA560F-D558-47A8-89D3-E5934BE32A9CQ36459685-21F929C3-7FA3-4F3D-9644-1F47300853D9Q36657320-DB1DEE2A-A009-46EF-BDB0-1177BE95E680Q36764263-3EEC1168-A1A1-4DA2-BC63-F0607B6EBF5EQ36869148-178E9D29-56CF-4C9C-B394-5EE12E9303A4Q37179387-D72DE4CF-4D60-4744-9E2D-265D6686BB40Q37609648-2BB21093-1108-4943-AD59-35444354D71BQ37629037-22602D67-8560-463D-B548-09D46FEEFCE6Q37730104-FA9EEFC6-0734-437C-B14F-C9D7C68EFDC6Q37970731-BBD70ABC-5027-4338-A2C2-9687350F28F5Q38017937-1274E38A-2FCC-487D-BED2-EB7B5C9B9D3AQ38174447-6E42FD35-CB3B-4F65-BCBD-312FB8F9D49DQ38323383-0B09BBB0-8E75-4681-964A-498C4C768FC4Q38390695-D7B01006-5849-4953-AFD8-63E5EBFA96D8Q38732060-6922C450-5F62-4DD5-AB1C-8A8A0B86195AQ38779151-883E4984-B2A9-485D-844E-8BC8E14DD911Q38818757-EB32AE31-4A83-4956-A39F-14F225E4831CQ38864535-213670D1-C8EB-40BC-9E57-03AC92C1BFA3
P2860
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@en
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@nl
type
label
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@en
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@nl
prefLabel
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@en
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@nl
P2093
P2860
P1476
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
@en
P2093
Hae-Young Yong
Min-Soo Koh
P2860
P304
P356
10.1517/13543780903321490
P407
P577
2009-12-01T00:00:00Z